Enovis (NYSE:ENOV) Director Angela Lalor Purchases 874 Shares of Company Stock

Key Points

  • Enovis Director Angela Lalor purchased 874 shares at $28.04 each, spending about $24,507. The purchase increased her direct ownership by 2.63% to 34,117 shares.
  • Enovis reported quarterly EPS of $0.88, beating the $0.77 consensus, while revenue of $558.73 million slightly exceeded estimates and rose 1.8% year over year.
  • Analysts have a “Moderate Buy” consensus rating and an average price target of $38.62; 10 analysts rate the stock Buy, one Hold, and one Sell.

Enovis Corporation (NYSE:ENOV - Get Free Report) Director Angela Lalor bought 874 shares of the firm's stock in a transaction on Thursday, November 12th. The stock was acquired at an average cost of $28.04 per share, for a total transaction of $24,506.96. Following the completion of the purchase, the director directly owned 34,117 shares in the company, valued at approximately $956,640.68. This represents a 2.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Enovis Trading Up 0.6%

Shares of Enovis stock opened at $27.85 on Tuesday. The stock has a market cap of $1.61 billion, a P/E ratio of -3.02 and a beta of 1.31. The stock's 50 day simple moving average is $20.71 and its 200-day simple moving average is $23.25. Enovis Corporation has a 1-year low of $16.70 and a 1-year high of $31.67. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.15 and a quick ratio of 1.08.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.77 by $0.11. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. The business had revenue of $558.73 million during the quarter, compared to analyst estimates of $557.12 million. During the same period in the prior year, the business earned $0.75 earnings per share. The business's revenue was up 1.8% compared to the same quarter last year. Analysts predict that Enovis Corporation will post 3.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In




Several analysts have issued reports on the company. Citigroup restated a "market outperform" rating on shares of Enovis in a report on Wednesday, September 2nd. Citizens Jmp lowered their price target on shares of Enovis from $55.00 to $47.00 and set a "market outperform" rating on the stock in a research report on Wednesday, September 2nd. Needham & Company LLC upped their price objective on shares of Enovis from $34.00 to $38.00 and gave the company a "buy" rating in a report on Thursday, November 5th. UBS Group restated a "buy" rating and set a $44.00 price objective on shares of Enovis in a research report on Monday, October 5th. Finally, Canaccord Genuity Group reduced their target price on shares of Enovis from $45.00 to $42.00 and set a "buy" rating on the stock in a research note on Friday, November 6th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Enovis presently has an average rating of "Moderate Buy" and a consensus target price of $38.62.

Get Our Latest Stock Analysis on Enovis

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. IFP Advisors Inc increased its stake in Enovis by 5,590.5% during the second quarter. IFP Advisors Inc now owns 1,195 shares of the company's stock worth $25,000 after acquiring an additional 1,174 shares during the last quarter. Allworth Financial LP acquired a new position in shares of Enovis in the 2nd quarter valued at $36,000. Integrated Wealth Concepts LLC purchased a new position in shares of Enovis during the 2nd quarter worth $39,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Enovis during the 2nd quarter worth about $48,000. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of Enovis during the 3rd quarter worth about $55,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

About Enovis

(Get Free Report)

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.

Featured Articles

Insider Buying and Selling by Quarter for Enovis (NYSE:ENOV)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Enovis?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Enovis and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles